Why the study?
Does etomidate increase 30-day mortality and cardiovascular morbidity compared to propofol in ASA III/IV patients undergoing noncardiac surgery?
Does etomidate increase 30-day mortality and cardiovascular morbidity compared to propofol in ASA III/IV patients undergoing noncardiac surgery?
Etomidate induction in high-risk patients undergoing noncardiac surgery is associated with a 2.5-fold increased odds of 30-day mortality compared to propofol.
No takes yet. Share an insight, caveat, or question.
May warrant caution with etomidate in high-risk noncardiac surgery; leaves open causality and need for randomized trials.
Komatsu et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: